A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

Abstract Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the majority of PLGG have activation of the MAPK/ERK pathway. The same pathway is also activated in plexiform neurofi...

Full description

Bibliographic Details
Main Authors: Sébastien Perreault, Valérie Larouche, Uri Tabori, Cynthia Hawkin, Sarah Lippé, Benjamin Ellezam, Jean-Claude Décarie, Yves Théoret, Marie-Élaine Métras, Serge Sultan, Édith Cantin, Marie-Ève Routhier, Maxime Caru, Geneviève Legault, Éric Bouffet, Lucie Lafay-Cousin, Juliette Hukin, Craig Erker, Nada Jabado
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Cancer
Subjects:
Trametinib
Glioma
Plexiform neurofibroma
Neurofibromatosis type 1
BRAF
MEK inhibitor
Online Access:https://doi.org/10.1186/s12885-019-6442-2

Internet

https://doi.org/10.1186/s12885-019-6442-2

Similar Items